Skip to main content
padlock icon - secure page this page is secure

Radiofrequency Radiation and Human Triiodothronine Hormone: Immunoenzymometric Assay

Buy Article:

$68.00 + tax (Refund Policy)

The aim of this study was to investigate whether the thyroid Triiodothronine (T3) levels in the serum could be interfered by the exposure to the 900MHz cell phones in the laboratory. We also reviewed a selected number of recent patents relevant to the area of RF radiation and biomarkers. Human serum samples from 29 healthy donors were labeled with ruthenium to form a sandwich complex based on an immunoassay technique. All of them were placed into two batches, and the well heads in the first batch were exposed to 900MHz exposure emitted from a GSM mobile phone simulator for 18 min. Unexposed batch was served as the control sample under identical conditions and was compared with the exposed one in quantitative determination of T3 using the Wilcoxon test with criterion level of P = 0.050. Using the Wilcoxon test, there was no significant difference in serum T3 in the exposed group compared to the control group (P = 0.541). More accurate follow up studies are needed for the evaluation of the effects of the mobile phone use. The results here should be confirmed in the in vivo situation on mammalians and in larger series.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Biomarkers; Triiodothronine; human thyroid hormone; immunoassay technique; mobile phone; radiofrequency radiation

Document Type: Research Article

Publication date: September 1, 2013

More about this publication?
  • Recent Patents on Biomarkers publishes review and research articles, and guest edited thematic issues on important recent patents on biomarkers. The coverage includes novel biomarkers in basic, medical, environmental, and pharmaceutical research. A selection of important and recent patents on biomarkers is also included in the journal. The journal is essential reading for all researchers involved in biomarker research and discovery. The journal also covers recent research (where patents have been registered) in fast emerging patent biomarker applications; discovery and validation are covered for drug discovery, clinical development and molecular diagnostics.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more